Lifestyle program for adults living with multiple myeloma
Tests a 16-week eating and exercise program in adults with multiple myeloma.
Plain-language title generated from the registry record
Registry title: Moving Forward With Myeloma: A Lifestyle Intervention for Individuals With Multiple Myeloma
Key facts
- Where
- Maywood and Milwaukee, United StatesSee the 2 sites
Where in United States
- Loyola University ChicagoMaywood, United StatesTaking people
- Medical College of WisconsinMilwaukee, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Medical College of Wisconsin
- Trial code
- NCT07236502
- Record updated
- 6 October 2026
- Original description
The purpose of this project is to evaluate the impact of a 16-week lifestyle program that promotes changes in eating and exercise patterns. The main questions the study will answer are:Read full original descriptionShow less
Moving Forward With Myeloma: A Lifestyle Intervention for Individuals With Multiple Myeloma
The purpose of this project is to evaluate the impact of a 16-week lifestyle program that promotes changes in eating and exercise patterns. The main questions the study will answer are:
Do improvements in eating and exercise patterns lead to improved physical function, quality of life and blood biomarkers of biologial aging among individuals with multiple myeloma? Participants will complete study activities 3-4 times during the study.
1. In-person assessment to measure physical function, height/weight, body composition, and includes a blood draw 2. Surveys completed online or on paper at home
Inclusion: Adult (≥ 18 years); Diagnosed with MM at least one year prior to study enrollment; 100 days post transplant (if applicable); Has access to a smart phone or device with internet access; Be deemed "clinically stable" by their physician guided by the following:; not expected to receive therapies beyond maintenance (for 100 days); no new significant myeloma symptoms (e.g., fractures, spinal stability concerns) meriting changes in anti-neoplastic therapies in the next 30 days; AND; stable performance status (ECOG 0-2) assessed in the last 3 months; No reports of severe pain > Grade 3 [defined by the NCI CTCAE as tumor, neurologic, bone, or other pain interfering with self-care ADLs (bathing, dressing, toileting, continence, feeding)]; Able to participate in PA and strength training per clinician approval and confirmed by participant; Able to understand and willing to sign a written informed consent document; English proficient for reading and writing.
Exclusion: Coexistent amyloidosis, POEMS syndrome will not be approached; Psychiatric or other clinical conditions that preclude study compliance; If participant is of child-bearing age they cannot be pregnant, planning to come pregnant or lactating during the study period; Fully adherent to the ACS nutrition and physical activity guidelines; On another interventional clinical trial that precludes co-enrollment; Other important medical or safety considerations at the discretion of the investigator(s) and/or approving clinician.